(Dual Agonist: GLP-1R / GIPR)

GLP-1T  is a synthetic dual incretin receptor agonist that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). This dual-pathway mechanism has been extensively investigated for its synergistic effects on glucose control, insulin sensitivity, lipid metabolism, and energy regulation in research models.

By combining the metabolic actions of both GLP-1 and GIP signaling, Tirzepatide represents an advanced next-generation incretin analog designed to explore multihormonal regulation of glucose and body-weight dynamics.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.

• GIPR activation: Supports insulin response and lipid metabolism while complementing GLP-1–mediated effects.

• Dual incretin synergy: Integrates complementary hormonal pathways to optimize metabolic outcomes.

• Energy expenditure modulation: Improves thermogenesis and fat oxidation in experimental settings.

• Cardiometabolic regulation: Demonstrates potential benefits on lipid profiles and inflammatory markers.

Potential Benefits (Based on Preclinical Research):

• Significant reduction in body-weight gain in obesity research models

• Improved insulin sensitivity and glucose tolerance

• Favorable effects on lipid metabolism and energy efficiency

• Enhanced appetite control and caloric balance

• Studied for applications in obesity, diabetes, and metabolic-syndrome research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

TB-500 – 5 mg

(Thymosin Beta-4 Fragment – Regenerative Peptide)

TB-500 is a synthetic peptide fragment of Thymosin Beta-4 (Tβ4), a naturally occurring protein involved in tissue regeneration and cellular migration. The active region of TB-500 is responsible for binding to actin, a fundamental component of the cellular cytoskeleton, promoting cell mobility, angiogenesis, and repair in experimental models.

This compound has been widely studied in wound healing, muscle recovery, and anti-inflammatory research, where it demonstrates the ability to accelerate tissue regeneration, support endothelial function, and modulate cellular response following injury.

Mechanism of Action (Based on Preclinical and Clinical Research):

• Actin-binding activity: Enhances actin polymerization, facilitating cell migration and structural remodeling.

• Angiogenesis promotion: Stimulates blood vessel formation through upregulation of VEGF and related growth factors.

• Cytoprotective signaling: Reduces inflammatory cytokine expression and oxidative stress markers.

• Fibroblast activation: Supports collagen synthesis and tissue remodeling in connective-tissue studies.

• Synergistic repair: Works complementarily with other regenerative peptides such as BPC-157.

Potential Benefits (Based on Preclinical Research):

• Accelerated healing of muscle, tendon, and ligament injuries

• Enhanced angiogenesis and tissue oxygenation

• Reduction of inflammation and oxidative damage

• Support for cellular regeneration and structural repair

• Studied for applications in cardiovascular, musculoskeletal, and regenerative-biology research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

TA-1 – 5 mg

(Thymosin Alpha-1 – Immunomodulatory Peptide)

Thymosin Alpha-1 (TA-1) is a synthetic 28-amino acid peptide originally isolated from thymic tissue and studied for its potent immunomodulatory and cytoprotective properties. It plays a critical role in the regulation of innate and adaptive immunity, influencing T-cell differentiation, cytokine signaling, and immune system resilience in preclinical models.

TA-1 has been extensively evaluated in research involving immune regulation, infection control, and cellular defense, making it a key compound for studies focused on immune restoration and anti-inflammatory pathways.

Mechanism of Action (Based on Preclinical and Clinical Research):

• T-cell modulation: Promotes differentiation and activation of T lymphocytes, enhancing immune response balance.

• Cytokine regulation: Modulates expression of IL-2, IFN-γ, and other immune mediators in experimental models.

• Innate immunity activation: Stimulates dendritic cells and natural killer (NK) cell activity.

• Cellular protection: Exhibits anti-inflammatory and antioxidant activity through regulation of NF-κB and redox signaling.

• Host defense support: Studied for its role in enhancing resistance to immune and oxidative stress.

Potential Benefits (Based on Preclinical Research):

• Enhanced immune system modulation and resilience

• Improved cellular defense and stress response

• Support for balanced inflammatory signaling

• Studied in viral, autoimmune, and immunosenescence models

• Applications in immune health, regenerative, and anti-inflammatory research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

Sermorelin – 10 mg

(Growth Hormone Releasing Hormone Analog – GHRH 1-29)

Sermorelin is a synthetic peptide analog of Growth Hormone Releasing Hormone (GHRH 1–29), corresponding to the biologically active fragment of endogenous GHRH. It acts on the pituitary somatotroph cells to stimulate natural, pulsatile release of growth hormone (GH) through activation of the GHRH receptor.

Sermorelin has been extensively investigated in research settings as a physiological GH secretagogue, providing a naturalistic alternative to exogenous GH administration. Its short half-life and pulsatile stimulation make it a valuable compound for studying endocrine regulation, growth mechanisms, and metabolic signaling in experimental models.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GHRH receptor activation: Binds to GHRH-R on pituitary somatotrophs, triggering GH synthesis and secretion.

• Physiologic GH pulsatility: Stimulates natural rhythmic GH release that promotes downstream IGF-1 production.

• Synergistic effects: Demonstrates amplified GH output when co-administered with GHRPs (e.g., GHRP-2, Ipamorelin).

• Metabolic influence: Supports anabolic processes, cellular recovery, and lipid metabolism in research systems.

• Neuroendocrine modulation: Regulates hypothalamic–pituitary feedback loops associated with aging and metabolism.

Potential Benefits (Based on Preclinical Research):

• Enhanced endogenous GH and IGF-1 production

• Improved muscle repair and tissue regeneration

• Support for metabolic balance and lipid utilization

• Studied for age-related GH decline and neuroendocrine health

• Applications in research involving pituitary function and anabolic regulation

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

(Glucagon-Like Peptide-1 Receptor Agonist – GLP-1R)

GLP-1S is a synthetic long-acting analog of human glucagon-like peptide-1 (GLP-1), developed to mimic the activity of endogenous incretin hormones that regulate glucose metabolism and energy balance. By selectively binding to and activating the GLP-1 receptor (GLP-1R), Semaglutide enhances insulin secretion, suppresses glucagon release, and delays gastric emptying in research models.

Its extended half-life—achieved through structural modification that enhances albumin binding—makes Semaglutide a widely studied compound for metabolic, obesity, and glucose-regulation research as part of the incretin-based therapeutic class.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion while inhibiting glucagon release.

• Gastric motility modulation: Slows gastric emptying to prolong nutrient absorption and satiety.

• Appetite suppression: Engages central GLP-1R pathways in the hypothalamus, influencing hunger regulation.

• Metabolic efficiency: Promotes improved lipid metabolism and insulin sensitivity in experimental systems.

• Extended duration: Albumin-binding modification extends biological activity up to one week in vivo.

Potential Benefits (Based on Preclinical Research):

• Enhanced glucose control and insulin responsiveness

• Reduced food intake and body-weight modulation

• Improved lipid and energy metabolism markers

• Cardiometabolic protection observed in experimental models

• Studied for applications in metabolic, obesity, and endocrine research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

(Triple Agonist: GLP-1R / GIPR / GCGR)

GLP-1R is a synthetic triple-agonist peptide that simultaneously targets the receptors for glucagon-like peptide-1 (GLP-1R), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon (GCGR). This multi-receptor approach has been investigated for its ability to coordinate multiple hormonal axes that influence energy expenditure, glucose metabolism, and body-weight modulation in research models.

By integrating GLP-1, GIP, and glucagon signaling, Retatrutide represents a next-generation incretin-based compound studied for its broad metabolic and cardiometabolic potential in experimental systems.

Mechanism of Action (Based on Preclinical and Clinical Research):

• GLP-1R activation: Stimulates insulin secretion, slows gastric emptying, and reduces appetite through central and peripheral pathways.

• GIPR activation: Enhances glucose-stimulated insulin release and complements GLP-1 action for improved glycemic control.

• GCGR activation: Increases basal energy expenditure and promotes fat oxidation through mild glucagon receptor engagement.

• Triple-pathway synergy: Coordinates metabolic hormone signaling to enhance lipid utilization and energy balance beyond single-agonist mechanisms.

Potential Benefits (Based on Preclinical Research):

• Significant body-weight reductions in obesity research models

• Improved glucose regulation and insulin sensitivity

• Enhanced energy expenditure and lipid metabolism

• Favorable effects on cardiovascular and metabolic biomarkers

• Studied for potential in multi-incretin and metabolic-disease research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

NAD⁺ – 100 mg

(Nicotinamide Adenine Dinucleotide – Cellular Energy Cofactor)

NAD⁺ (Nicotinamide Adenine Dinucleotide) is a vital coenzyme present in all living cells, essential for cellular energy production, redox balance, and metabolic regulation. It plays a critical role in oxidative phosphorylation and acts as a substrate for key enzymatic processes, including sirtuins, PARPs (poly ADP-ribose polymerases), and CD38, which regulate DNA repair, mitochondrial health, and cellular aging.

In research settings, NAD⁺ has been extensively studied for its role in mitochondrial function, neuroprotection, and cellular longevity, making it a central focus of metabolic and anti-aging investigations.

Mechanism of Action (Based on Preclinical and Clinical Research):

• Redox cofactor: Functions as an electron carrier in oxidation-reduction reactions central to ATP production.

• Sirtuin activation: Serves as a substrate for SIRT enzymes that regulate metabolism, stress resistance, and genomic stability.

• DNA repair support: Provides substrate for PARP-mediated DNA repair mechanisms.

• Mitochondrial regulation: Enhances mitochondrial biogenesis and energy efficiency under stress conditions.

• Cellular protection: Modulates oxidative stress, inflammatory pathways, and apoptosis.

Potential Benefits (Based on Preclinical Research):

• Improved mitochondrial performance and ATP synthesis

• Support for cellular repair and genomic stability

• Enhanced resistance to oxidative and metabolic stress

• Neuroprotective and cardioprotective potential

• Investigated for applications in longevity, metabolic health, and cellular rejuvenation research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

MT-2 – 10 mg

(Melanotan II – Synthetic α-MSH Analog)

MT-2 (Melanotan II) is a synthetic cyclic heptapeptide and potent analog of α-melanocyte-stimulating hormone (α-MSH). It binds to and activates melanocortin receptors (MC-1R, MC-3R, MC-4R, and MC-5R), influencing pigmentation, energy homeostasis, sexual function, and appetite regulation in experimental models.

Developed as a stable, long-lasting analog of the natural melanocortin peptide, MT-2 has been widely studied for its ability to induce melanogenesis, enhance photoprotection, and modulate neuroendocrine and metabolic responses through the central melanocortin system.

Mechanism of Action (Based on Preclinical and Clinical Research):

• Melanocortin receptor activation: Binds primarily to MC-1R on melanocytes, increasing melanin synthesis and skin pigmentation.

• Photoprotective response: Stimulates eumelanin production, providing UV-resistant pigmentation in research models.

• Neuroendocrine modulation: Engages MC-3R and MC-4R receptors involved in appetite, energy expenditure, and sexual behavior.

• Anti-inflammatory pathways: Demonstrates modulation of cytokine and oxidative-stress activity.

• Extended half-life: Cyclization of the peptide backbone improves stability and duration compared to natural α-MSH.

Potential Benefits (Based on Preclinical Research):

• Induction of skin pigmentation and photoprotective effects

• Regulation of appetite and energy balance via central melanocortin pathways

• Support for neuroendocrine and metabolic research

• Investigation into libido and sexual-function modulation

• Studied for antioxidant and anti-inflammatory properties in cellular models

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

Ipamorelin – 5 mg

(Selective Growth Hormone Secretagogue – GHSR Agonist)

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone releasing peptide (GHRP) family. It functions as a selective ghrelin receptor (GHS-R1a) agonist, stimulating the pituitary gland to release endogenous growth hormone (GH) while exhibiting minimal impact on cortisol or prolactin levels.

Distinguished by its high selectivity and mild physiological profile, Ipamorelin is frequently used in research as a refined model for exploring GH modulation, cellular repair, and anabolic metabolism without the unwanted side effects observed in earlier GHRPs.

Mechanism of Action (Based on Preclinical and Clinical Research):

• Ghrelin receptor activation: Binds to GHS-R1a receptors, inducing natural GH pulse release.

• Selective GH stimulation: Triggers growth hormone secretion without significantly altering ACTH, cortisol, or prolactin.

• Synergistic interaction: Demonstrates additive GH release when combined with GHRH analogs (e.g., CJC-1295).

• Anabolic and metabolic support: Enhances protein synthesis and cellular repair processes in metabolic models.

• Neuroendocrine balance: Supports energy regulation and recovery through hypothalamic-pituitary modulation.

Potential Benefits (Based on Preclinical Research):

• Increased pulsatile GH and IGF-1 production

• Enhanced muscle recovery and protein synthesis

• Minimal effect on appetite and prolactin compared to GHRP-6 or Hexarelin

• Support for tissue regeneration and metabolic regulation

• Studied for potential applications in aging, repair, and hormone-regulation research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.

Hexarelin – 5 mg

(Growth Hormone Releasing Peptide Analog)

Hexarelin is a potent synthetic hexapeptide and member of the growth hormone secretagogue (GHS) family, closely related to GHRP-2 and GHRP-6. It acts as a selective agonist of the ghrelin receptor (GHS-R1a), stimulating the pituitary gland to release endogenous growth hormone (GH) in a pulsatile manner.

Compared to other GHRPs, Hexarelin is noted for its higher GH-releasing potency and consistent response even with repeated dosing in research models. It has been widely investigated for its potential roles in muscle repair, metabolic regulation, and cardiovascular protection.

Mechanism of Action (Based on Preclinical and Clinical Research):

• Ghrelin receptor activation: Binds selectively to GHS-R1a, triggering GH release from the anterior pituitary.

• Synergistic GH release: Enhances pulsatile GH secretion and may increase IGF-1 production.

• Anabolic signaling: Supports protein synthesis and tissue regeneration via GH/IGF-1 pathways.

• Cardioprotective effects: Studied for myocardial and vascular protective properties in experimental models.

• Metabolic influence: May improve lipid and glucose metabolism while supporting cellular recovery.

Potential Benefits (Based on Preclinical Research):

• Sustained elevation of endogenous GH levels

• Promotion of muscle growth and tissue recovery

• Support for cardiac and vascular function

• Enhanced metabolic activity and fat utilization

• Synergistic applications with GHRH analogs (e.g., CJC-1295) in GH-releasing studies

• Explored for regenerative and performance-related biological research

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.